Sanfilippo et al reported the IMPEDE VTE score for predicting venous thromboembolism (VTE) in a patient with patient with multiple myeloma. The authors are from multiple institutions in the United States.
Patient selection: multiple myeloma
Letter
Parameter
Points
I
immunomodulatory drug
4
M
BMI >= 25 kg per square meter
1
P
pelvic, hip or femur fracture
4
E
erythropoiesis-stimulating agent
1
D
doxorubicin
3
D
dexamethasone, high dose (>= 480 mg monthly)
4
D
dexamethasone, low dose
2
E
ethnicity Asian or Pacific Islander
-3
V
history of VTE prior to myeloma
5
T
tunneled line or central venous catheter
2
E
existing therapeutic low molecular weight heparin or vitamin K antagonist
-4
E
existing prophylactic low molecular weight heparin or vitamin K antagonist
-3
score =
= SUM(points for all of the parameters)
Interpretation:
• minimum score: -7
• maximum score: 24
Score
Risk of VTE
<= 3
low
4 to 7
intermediate
>= 8
high
Performance:
• The area under the ROC curve ranges from 0.64 and 0.66.
To read more or access our algorithms and calculators, please log in or register.
